Vice President of Information Technology

REGENXBIO schedules October 20 event: REGENXBIO stock gains 8.87 percent. Published on 10/20/2026 at 19:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Sura-vec event was set for October 20, 2026. REGENXBIO stock costs EUR 6.70 on October 20, 2026, up 8.87 percent versus Tradegate close. Reporting date October 20, 2026. * REGENXBIO scheduled its Sura-vec investor event for October 20, 2026. * Second-quarter 2026 revenue reached USD 108.02 million, USD 10.39 million above consensus. * REGENXBIO stock costs EUR 6.70 at Lang & Schwarz on October 20, 2026 at 7:49 p.m. CEST, 8.87 percent above the Tradegate close of October 16, 2026. * The next quarterly update is listed for November 5, 2026. REGENXBIO (US75901B1070) had scheduled its Sura-vec investor event for October 20, 2026, highlighting surabgene lomparvovec in wet age-related macular degeneration, according to REGENXBIO. The stock was trading at EUR 6.70 at Lang & Schwarz on October 20, 2026 at 7:49 p.m. CEST, up 8.87 percent versus the Tradegate close of October 16, 2026 at EUR 6.15. Revenue beat adds financial support. The company's second-quarter 2026 revenue reached USD 108.02 million, compared with consensus of USD 97.63 million, a difference of USD 10.39 million. MarketBeat reported that adjusted earnings per share were USD 0.43, above the USD 0.08 consensus estimate, for the quarter ended June 30, 2026. Stock stays below the yearly high. At EUR 6.70, the Lang & Schwarz price stood 53.79 percent below the 52-week high of EUR 14.50 and 40.70 percent above the 52-week low of EUR 4.76. The primary Nasdaq listing last traded at USD 7.53 on October 20, 2026 at 1:56 p.m. ET, while the year-low and year-high levels were USD 5.46 and USD 16.19. Analyst targets remain a counterweight. Investing.com reported that Mizuho initiated coverage on October 5, 2026 with an Outperform rating and a USD 22.00 price target. That target lies 192.16 percent above the USD 7.53 Nasdaq price. The rating also identified RGX-202 and ABBV-RGX-314 as key assets, while clinical and regulatory execution remain material factors. What dates shape the next step? wallstreetONLINE lists November 5, 2026 as the next quarterly update. The October 20 event therefore sits between the June 30 reporting period and the next scheduled corporate date. Market value and trading context. REGENXBIO's market capitalization was USD 497.1 million as of October 20, 2026, with a negative price-to-earnings ratio of 1.99. Its gene therapy pipeline covers retinal, neuromuscular and neurodegenerative diseases, according to the company profile. REGENXBIO stock was trading at EUR 6.70 at Lang & Schwarz on October 20, 2026 at 7:49 p.m. CEST, 8.87 percent above the Tradegate close of October 16, 2026 at EUR 6.15. The further course of trading is shown by the continuously updated real-time quote of REGENXBIO stock. REGENXBIO stock facts. * Company: REGENXBIO Inc. * ISIN: US75901B1070 * Ticker: RGNX * Primary exchange: Nasdaq * Price Lang & Schwarz (as of October 20, 2026, 7:49 p.m. CEST): EUR 6.70 * Change versus Tradegate close: plus 8.87 percent * Tradegate close (October 16, 2026): EUR 6.15 * Market capitalization: USD 497.1 million (as of October 20, 2026) * 52-week range: USD 5.46-16.19 (as of October 20, 2026) * Sector / Industry: Biotechnology * Next earnings date: November 5, 2026 Sponsored Ad Regenxbio stock: new analysis - 22 October. Fresh Regenxbio information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | US75901B1070 | RGNX | boerse | 70377039 | bgmi

REGENXBIO's diabetic eye gene therapy reaches three-year mark. Six of ten patients in a small trial improved by two or more steps on a severity scale after one treatment, though the data are interim. Most treatments for diabetic eye disease ask patients to come back again and again for injections. REGENXBIO is testing whether one visit could do the job for years, and its latest numbers, presented at the Retina Society's 59th Annual Scientific Meeting in Los Angeles, are worth a careful read [1]. The company reported three-year follow-up data (as of 17 August 2026) from its Phase II ALTITUDE trial of surabgene lomparvovec, or sura-vec (also known as ABBV-RGX-314, developed in collaboration with AbbVie). Participants had non-proliferative diabetic retinopathy, the earlier stage of the disease, before abnormal blood vessels start growing in the eye. Sura-vec is a gene therapy. Doctors deliver it in a single in-office procedure, and it uses a viral vector (a modified virus that works as a delivery vehicle) to carry instructions into cells at the back of the eye. Those cells then make a fragment of an antibody that blocks VEGF, a protein that encourages new, leaky blood vessels to form and fluid to build up in the retina. Today's anti-VEGF injections do a similar job from the outside, which is why they have to be repeated. The gene therapy is meant to turn the eye into its own supplier. For the patients in this analysis, the treatment came with a short course of steroid eye drops to head off inflammation. Among participants who received Dose Level 3 and had three-year visits, 60% improved by two or more steps on the Diabetic Retinopathy Severity Scale (DRSS), the grading system eye doctors use to rate how advanced the disease is. That's six out of ten people. None of them needed additional treatment for diabetic retinopathy, and none had vision-threatening events. There's a second finding. Four participants had improved by one step at year one without extra anti-VEGF injections, and three of those four went on to reach a two-step improvement by year three, again without further treatment. Across 17 participants followed through three years, the company saw no intraocular inflammation and no new safety signals related to sura-vec. Dr Steve Pakola, chief medical officer of REGENXBIO, called the results "highly encouraging," and said the durability "strengthens our conviction in sura-vec as a potentially transformative, one-time treatment." Ten patients is a very small group. The company also says these are interim results from analyses it performed itself, in an ongoing trial. And 60% still means four of the ten didn't hit the two-step mark, though the release doesn't explain what happened with them. There's a footnote worth knowing about, too. One participant who reached a two-step improvement at year two later received two supplemental anti-VEGF injections. Their investigator chose to treat the study eye at the same time as the other eye, which needed treatment for swelling in the center of the retina, even though the study eye showed no sign of progression. That participant was then lost to follow-up and has no year-three data. It's a reminder of how messy real patients are, and how a tidy percentage can sit on top of judgment calls. The dose is being carried forward regardless. Dose Level 3 is now being tested in the larger Phase IIb/III NAAVIGATE trial in the same patient group. Dr Nikolas London, a retina specialist at Retina Consultants San Diego and an ALTITUDE investigator, explained why the goal matters. "For patients with non-proliferative diabetic retinopathy, the goal is to intervene before the disease progresses to vision-threatening complications and irreversible vision loss," he said. "However, current preventive treatment requires repeat injections, which is a significant burden for a population that is largely working-age adults." That burden isn't small. Diabetic retinopathy is the leading cause of vision loss in adults between 24 and 75 worldwide, and it affects nearly 10 million people in the United States alone. For patients at the earlier stage, the current options are typically "watchful waiting" or anti-VEGF treatment. The longevity angle. Diabetes wears on the body slowly, and the eye is one of the places it shows first. Losing sight in midlife or later means losing independence, work, driving, reading, the little things that make a long life feel like one worth having. A single treatment that could hold off that decline would fit neatly into the longevity field's growing interest in one-time therapies for chronic problems, rather than lifelong maintenance. Whether sura-vec earns that place depends on bigger trials. For now it's an early, small, carefully hopeful signal. LTUI: 2865 Regenxbio. Powered by: Longevity level(s): * Level 5: Aging disease management * Level 7: Targeted aging disease reversal Overview. Regenxbio is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV) gene therapies designed to deliver functional genes to cells for the treatment of genetic defects and rare diseases. The company's proprietary NAV(R) Technology Platform enables targeted delivery of therapeutic genes to address underlying disease causes across retinal, metabolic, and neurodegenerative therapeutic areas. Through single-administration treatments intended to provide long-lasting effects, Regenxbio aims to significantly alter disease progression and improve patient outcomes for individuals with serious unmet medical needs. Access all data points on DLT: * Financial Data * Patents * Technology * Management * Advisory Board * News * Classifications * Similar Companies